Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/13—Amines
  • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
  • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/2004—Excipients; Inactive ingredients
  • A61K9/2009—Inorganic compounds
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/2004—Excipients; Inactive ingredients
  • A61K9/2013—Organic compounds, e.g. phospholipids, fats
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/02—Inorganic compounds
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
  • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
  • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
  • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
  • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame

Definitions

• Solubilized Sertraline Compositions Field of the Invention relates to a composition comprising sertraline or a pharmaceutically acceptable salt thereof and a solubilizing agent which prevents gel formation or otherwise maintains the solubility of sertraline in a use environment containing chloride ions.
• the invention further relates to a method of treating a psychiatric or other illness comprising administering sertraline in such a solubilized composition to a mammal, including a human patient, in need of such treatment.
• Sertraline is a selective serotonin reuptake inhibitor (SSRI), which is useful as an antidepressant and anorectic agent, and in the treatment of obsessive-compulsive disorder, premenstrual dysphoric disorder, post-traumatic stress disorder, chemical dependencies, anxiety-related disorders, panic and premature ejaculation.
• SSRI selective serotonin reuptake inhibitor
• Sertraline is most commonly prescribed for therapy of depressive illness, in the general dose range 50-200 mg/day. Sertraline has an elimination half-life of 23 hr and is dosed once daily.
• sertraline is available as the hydrochloride salt which is undeniably therapeutically effective, many patients having availed themselves of the benefits of this drug.
• Such salts generally those having an aqueous solubility in excess of 10 mg/mL, can exhibit a tendency to form a gel and/or exhibit reduced solubility (e.g., precipitate as a salt or as the free base having a lower solubility in the environment of use than the salt form originally administered) when exposed to a use environment containing chloride ions such as the gastrointestinal tract.
• the gel itself tends to dissolve slowly and otherwise releases sertraline at a slow rate, thereby affecting absorption. It is not known whether gelation is the only mechanism which impacts the solubility of sertraline in a use environment.
• sustained-release dosage forms can be detrimental in those sustained release systems known as non-eroding matrix systems, reservoir systems, and osmotic systems.
• release of the drug is dependent on transport of the drug across a distance within the device (matrix or coating layer) to the surrounding fluid. This drug transport can occur by diffusive or convective mechanisms. In both mechanisms, formation of a gel can reduce transport by an order of magnitude or more and in some cases can result in devices that exhibit incomplete drug release (e.g., less than 70% of the total drug in the formulation).
• composition of matter suitable for administration to a mammal, including a human, comprising sertraline or a pharmaceutically acceptable salt thereof and an amount of an excipient, herein termed a "solubilizing agent" sufficient to effect a concentration of dissolved sertraline in a use environment containing chloride ions which is at least 1.5 times higher, preferably 2 times higher, more preferably 3 times higher than the concentration effected by a comparative composition of matter (i.e., a control) identical thereto but for the inclusion of said solubilizing agent.
• a solubilizing agent sufficient to effect a concentration of dissolved sertraline in a use environment containing chloride ions which is at least 1.5 times higher, preferably 2 times higher, more preferably 3 times higher than the concentration effected by a comparative composition of matter (i.e., a control) identical thereto but for the inclusion of said solubilizing agent.
• compositions are suitable for formulating into oral dosage forms including tablets, capsules, multiparticulates, powders for oral suspension, and unit dose packets (sometimes referred to in the art as a "sachet").
• the compositions can be used in liquid dosage forms such as oral solutions or suspensions and injectable formulations.
• conventional techniques known to the art can be employed.
• the composition can additionally comprise other conventional pharmaceutical ingredients and/or a pharmaceutically acceptable carrier.
• solubility may advantageously be increased, and in some cases solution viscosity may be advantageously decreased, by employing the sertraline salt together with a solubilizing agent which increases the sertraline's solubility.
• the solubilizing agent preferably also maintains solubility, meaning that the level of dissolved sertraline in a use environment, regardless of the salt employed, is held at a concentration greater than or equal to 1.5 times the concentration of sertraline in a like formulation without solubilizing excipient, for at least 2 hours.
• the sertraline concentration may be advantageous to maintain the sertraline concentration greater than or equal to 1.5 times the concentration of sertraline in like formulations without solubilizing excipient for longer periods of time such as 4 hours, 8 hours, 16 hours, or 20 hours, and this can be effected by the choice and amount of solubilizing agent.
• sertraline solubility is generally less than 10 mgA/mL, usually less than 5 mgA/mL, regardless of the salt employed, and despite the fact that many of the salts themselves exhibit solubilities in pure water (i.e., no chloride ions) well in excess of 10 mgA/mL Solubilizing agents thus could also be construed to be compounds that maintain sertraline concentrations of 10mgA/ml or greater in chloride-ion-containing environments of use.
• solubilizing agent herein, including the claims, shall be understood as also including the use of more than one solubizing agent in a composition, added separately or as a mixture.
• the term "use environment" can refer to the aqueous in vivo chloride ion-containing digestive fluids of the stomach, or to an in vitro chloride ion-containing aqueous environment used to test a dosage form for its sertraline release characteristics.
• a useful in vitro test environment for purposes of this invention is 0.075M sodium chloride. 0.075M sodium chloride is preferred as a test medium because of its ready availability and similar chloride ion concentration to the lower levels of chloride ions found in the fluids in the Gl tract. Blood & Other Body Fluids. Dorothy S. Dittmer, ed., Federation of American Societies for Experimental Biology, Washington, D.C., 1961, pp. 404-419.
• this invention provides an in vitro test to determine whether a dosage form is within the scope of the invention. That is, the invention provides a composition of matter comprising sertraline or a pharmaceutically acceptable salt thereof and an amount of a solubilizing agent sufficient to produce and to maintain, for at least 2 hours in 0.075M sodium chloride, a concentration of dissolved sertraline which is at least 1.5 times higher than the concentration effected by a comparative composition of matter identical thereto but for the inclusion of said solubilizing agent. Agitation should be employed during the test although, as explained below, the degree or type of agitation is not critical. Salt solution temperature is not believed to be particularly critical so long as it is about 37°C, plus or minus 3°C, throughout the test.
• Excipients including the solubilizing agent(s) should be at the desired concentration in the aqueous test solution prior to adding sertraline and sodium chloride.
• Sertraline is then added to a concentration ranging between 80% to 100% of its saturation concentration in the test solution. This solution should be decanted off or filtered away from any solids.
• a 3M NaCl solution is slowly added with stirring until the NaCl concentration in the test solution is 0.075M.
• the sertraline concentration in this test solution after 2 hours is compared with a control solution made in the same manner and consisting of the same components except the solubilizing agent.
• a solubilizing excipient can be identified in an in vivo test such as a crossover study.
• a solubilized sertraline- containing dosage form is dosed to half a group of 12 or more humans and, after an appropriate washout period (e.g., one week) the same subjects are dosed with a dosage form otherwise identical but for inclusion of the solubilizing agent.
• the other half of the group is dosed with the non-solubilized dosage form first, followed by the solubilized dosage form.
• Maximum concentration in the blood (C max ) and/or bioavailability, measured as the area under the curve (AUC) for a plot of the concentration of sertraline in blood versus time, is determined for each group.
• the solubilizing excipient is an embodiment of this invention. It is preferred that the C max and/or AUC be greater by at least 15%, and more preferred either or both be greater by at least 20%.
• the determination of AUC's is a well known procedure and is described, for example, in "Pharmacokinetics; Processes and Mathematics,” by Peter Welling (ACS Monograph 185, Amer. Chem. Soc, Wash. D. C, 1986).
• the invention provides a composition of matter comprising sertraline or a pharmaceutically acceptable salt thereofand an amount of a solubilizing agent sufficient to effect, in vivo, a C max and/or an AUC which is greater by at least 10% than the C max and/or AUC effected by a comarison composition of matter (i.e., a control) identical thereto but for the inclusion of said solubilizing agent.
• the invention further provides a method of increasing the solubility of sertraline in an aqueous chloride ion-containing environment, comprising administering said sertraline in a composition of matter comprising sertraline and a solubilizing agent.
• the invention is surprising in that, prior to the invention, it was not known that (1) the phenomenon of reduced sertraline solubility in chloride ion-containing environments existed, nor that (2) any chemical agent existed which would reduce or prevent sertraline gelation or reduced sertraline solubility in chloride ion-containing use environments or otherwise operate to increase sertraiine's solubility in such use environments.
• the term "solubilized sertraline” is used herein to refer to a composition comprising sertraline or a sertraline salt plus an excipient (i.e. the solubilizing agent) which prevents gelation or otherwise increases, and preferably maintains, the solubility of the sertraline salt in an in vivo or in vitro chloride ion- containing use environment.
• the term “solubilize” is used to denote that the solubility of a sertraline salt is being increased by at least 1.5 times in a use environment over what it would be in the absence of a solubilizing agent.
• the invention is preferred for use with the aspartate, acetate, and iactate salts which are salts that exhibit high solubilities in water relative to the free base.
• these salts are disclosed in commonly assigned co-pending application PC9337JTJ, filed as a PCT application designating the United States, and herein incorporated by reference.
• sertraline in terms of therapeutic amounts herein, including the claims, is to active sertraline, abbreviated herein as "mgA", i.e., the non-salt, non-hydrated free base having a molecular weight of 306.2. Amounts in mgA can conveniently be converted to equivalent weights for whatever salt form is desired.
• solubilizing agents useful herein can be grouped into several broad categories:
• Partial Glycerides i.e., less than fully esterified derivatives of glycerin, including monoglycerides and diglycerides;
• solubilizing agent employed in a composition according to the invention depends on the particular solubilizing agent employed.
• solubilizing agents which are organic acids
• solubilizer can be calculated as a ratio multiplied by the quantity of sertraline to be used, wherein the ratio is of organic acid solubility to solubility of sertraline salt:
• organic acid or salt solubility/sertraline or sertraline salt solubility x quantity of sertraline where the solubilities referred to are in mg/ml.
• the above expression is approximate, and some adjustment may be advantageous for optimization. Generally the above expression will give a quantity which is plus or minus 25% of the final value employed, although higher quantities of solubilizing agent can be incorporated without any particular additional advantage.
• organic acid salts can be added to modify the pH and/or solubility of the organic acid, effectively optimizing the solubilization effect of the agents.
• solubilizing agent employed in the dosage form will be 1 to 150% by weight of the amount of sertraline employed therein, preferably 1 to 100%, more preferably 3 to 75%. Amounts of solubilizing agent higher than 150% may be employed, although it is believed that in most cases no particular advantage would be provided.
• Salts of sertraline or excipients that in combination with sertraline aid in solubilizing sertraline can be beneficial to virtually any type of sertraline dosage forms intended for oral administration, including immediate release as well as controlled release systems, including (1) sustained-release dosage forms which meter out sertraline as they progress through the gastrointestinal system and (2) delayed release systems which release sertraline after an initial delay period following ingestion. Immediate-release systems are well known and commercially available in both solid and liquid formulations. Controlled release dosage forms of sertraline are discussed and disclosed in commonly assigned co-pending applications Pfizer Docket PC9337JTJ and PC9824JTJ, each of which is a PCT application designating the United States and each herein incorporated by reference in its entirety.
• Solubilized sertraline can enhance release from the dosage form by increasing the concentration gradient for diffusive based systems such as matrix dosage forms and reservoir dosage forms. Solubilized sertraline can also enhance delivery from osmotic dosage forms in that a more soluble sertraline can increase the osmotic pressure in the core and increase the sertraline concentration in the fluid that is pumped or extruded out of the dosage form. In addition, solubilized sertraline can benefit sustained-release formulations by aiding absorption of drug from the G.I. tract. For example, higher concentrations of drug in the colon can increase absorption due to a higher concentration gradient across the intestinal wall.
• organic acids useful in the invention include malic, citric, erythorbic, adipic, glutamic, aspartic, maleic, aconitic, and ascorbic acid.
• Preferred acids are citric, erythorbic, ascorbic, glutamic, and aspartic.
• Salts of organic acids such as alkalkine earth metal (magnesium, calcium) salts and alkali metal (lithium, potassium, sodium) salts are also effective as well as mixtures of organic acids and their salts.
• Calcium salts such as calcium carbonate, calcium acetate, calcium ascorbate, calcium citrate, calcium gluconate monohydrate, calcium lactobionate, calcium gluceptate, calcium levulinate, calcium pantothenate, calcium proprionate, calcium phosphate dibasic, and calcium saccharate are preferred organic acid salts.
• compositions include mixtures of an organic acid with or without a corresponding organic acid salt, and one or more of the non-organic solubilizers listed above or in Table 1.
• solubilizer in order to be most effective should have a solubility in the aqueous chloride-ion containing use environment of at least 1 mg/ml, and preferably greater than 5mg/ml.
• a preferred group of solubilizing agents, in addition to the preferred organic acids previously mentioned, includes those in Table 2.
• solubilizing agents include (1) an organic acid plus a salt of the same or a different organic acid, (2) an organic acid plus a non-ionic solubilizing agent such as any of those listed in Table 1 , and (3) an organic acid plus a salt of the same or a different organic acid plus a non-ionic solubilizing agent.
• Particularly preferred individual solubilizing agents include aspartic acid, glyceryl monocaprylate, glyceryl monolaurate, calcium acetate, ascorbic acid, citric acid, glutamic acid, and calcium carbonate. Aspartic acid, glyceryl monocaprylate, glyceryl monolaurate and calcium acetate are most preferred.
• a dosage form can be tested in vitro to determine whether an excipient has a solubilizing effect on sertraline in a chloride-ion containing use environment and thus is useful as a solubilizing agent.
• a 0.075M NaCl solution is preferred for use as a test medium although other chloride-ion containing solutions with equivalent or higher chloride ion concentration than 0.075M (e.g., 0.1N HCI or isotonic saline) may be used to determine the solubilizing effect of a test excipient.
• chloride-ion containing solutions with equivalent or higher chloride ion concentration than 0.075M e.g., 0.1N HCI or isotonic saline
• reduced solubility is evident simply by adding a dosage form such as a powder to the test medium because gelation is visible.
• a dosage form such as a tablet if the tablet is, for example, cut open and gelation is visible on its open face.
• a recommended procedure is to initially make a solution containing the desired excipients, including solubilizing agent(s).
• the excipients can be at any concentration relevant to the intended dosage form, but are typically for organic acids and soluble salts or sugars 80-100% of saturation.
• concentrations typically range from 1 to 150% of the sertraline concentration in the test solution.
• Sertraline is added to this excipient- containing solution at a concentration typically 80-100% of saturation.
• the solution is filtered or decanted to remove any solids and then a 3M solution of sodium chloride is added until the sodium chloride concentration is 0.075M.
• the concentrated sodium chloride solution should be added dropwise with stirring.
• This test medium should be kept at a temperature on the order of 37°C for at least 2 hours at which time the sertraline concentration in solution is determined. It is preferred that the sertraline concentration be maintained for 4 hours, more preferably for 8 hours, still more preferably for 16 hours, and most preferably for at least 20 hours.
• the amount of agitation is not critical. When sampling the test medium, filtration or centrifugation can be employed to obtain solution that is free of any solids or gel material, and also to avoid inclusion of particuiates (which may contain sertraline) in the sample.
• sertraline concentrations can be determined using reverse phase HPLC with a ULTRACARB ® 5 ODS 4.6 x 250 mm column (Phenomonex, Torrance, CA), and a mixture of acetic acid, triethylamine, acetonitrile, and water as mobile phase, with UV detection at 230 nm.
• the mobile phase can be prepared by combining, with stirring, 2.86 ml of glacial acetic acid, 3.48 ml of triethylamine, diluting to a liter with water, and filtering and degassing. Flow rates are typically on the order of 1.5 ml/min, and retention times about 4 minutes.
• Dosage forms with solubilizing agent can be formulated by conventional techniques.
• Immediate release dosage forms can be capsules, tablets, multipartic- ulates, liquid solutions or suspensions.
• Capsule formulations can be either soft gelatin capsules where the sertraline is either dissolved or suspended within the capsule core or hard gelatin capsules filled with multiparticulates, tablets or a liquid (solution or suspension) fill.
• Immediate release tablets can be by techniques standard in the industry by simply including the solubilizing agent as one or more of the tablet excipients.
• immediate-release multiparticulates can be made that include solubilizing agents by techniques such as extension spheronization, rotary granulation, coating seed cores or other methods common in the pharmaceutical industry.
• Liquid formulations consisting of a solution or suspension or both can be made by methods common in the pharmaceutical industry.
• Controlled-release dosage forms can also be made that include solubilizing agents by methods common in the pharmaceutical industry.
• Controlled release dosage forms include a wide variety of dosage forms that impart control over the dissolution rate or rate of release of sertraline from the dosage form.
• Such dosage forms include but are not limited to sustained release, delayed and then immediate release, delayed and then sustained release and a dosage form with a small portion of sertraline released immediately and then followed by the majority of the sertraline in the dosage release at a sustained rate.
• Other algorithms of release can also be attained such as pulsitile release. Many such formulations are described in aforementioned co-pending applications PC9337JTJ and PC9824JTJ.
• Standard techniques can be used to make controlled release dosage forms.
• tablets can be made by commonly used direct compression methods that contain sertraline and a solubilizing agent.
• a pH- sensitive coating can be applied to these tablets via a side-vented pan coater (e.g., HCT-60 tablet coater, Vector Corp.).
• the pH sensitive coating is resistant to low pH environments such as typically in the stomach and then dissolves, releasing sertraline, in neutral pH environment such as typically in the small intestine.
• Such coating materials e.g., cellulose acetate phthalate or methacryiic acid copolymer
• the tablets can be coated with a porous or semipermeable membrane coating to provide sustained release of the tablet cores.
• a particularly useful process for applying a membrane coating comprises dissolving the coating polymer in a mixture of solvents chosen such that as the coating dries, a phase inversion takes place in the applied coating solution, resulting in a membrane with a porous structure.
• solubilizing agents such as matrix systems which include but are not limited to 1) non-eroding matrices, tablets, multiparticulates and hydrogel-based systems; 2) hydrophilic eroding, dispersible or dissolvable matrix systems, tablets and multiparticulates; and 3) coated matrix systems.
• Another class of controlled-release dosage forms consists of reservoir systems where release of the drug is modulated by a membrane, such as capsules and coated tablets or multiparticulates.
• a third class consists of osmotic- based systems such as 1) coated bilayer tablets; 2) coated homogeneous tablet cores; 3) coated multiparticulates; and 4) osmotic capsules.
• a fourth class consists of swellable systems where drug is release by a swelling and then extrusion of the core components out through a passageway in a coating or surrounding shell or outer layer.
• Example 1 The invention is further illustrated by the following examples, which are not to be taken as limiting.
• Example 1 The invention is further illustrated by the following examples, which are not to be taken as limiting.
• Preferred acids are malic, citric, erythorbic, and adipic acids.
• Maieic, L-aspartic, tartaric, and L-glutamic acids also significantly improved sertraline hydrochloride solubility.
• Some controlled-release dosage forms with such acids in the core will perform better than those without such acids. This is particularily true for osmotic-based formulations that deliver a solution of drug.
• Example 2 This example illustrates that organic acids have the ability to raise the solubility of the acetate salt of sertraline by a test method similar to that used for the hydrochloride salt described in Example 1.
• the solubilizing agent, its concentration, and resulting sertraline solubility are shown in Table 2-1 below. Based on these results, preferred acids to include in a dosage form where increased sertraline acetate solubility is desired are ascorbic, erythorbic, citric, lactic, aspartic, glutamic, and aconitic acids.
• This example illustrates that organic acids and three calcium salts have the ability to raise the aqueous solubility of the lactate salt of sertraline using a method similar to that used for the hydrochloride salt described in Example 1.
• the solubilizing agent, its concentration in the aqueous test solution, and the sertraline lactate solubility in the test solution are listed in Table 3-1 below.
• Solubility of sertraline lactate in water is approximately 125 mg/ml.
• the data below show that eight organic acids effected sertraline lactate solubilities about the same as or higher than 125 mg/ml; adipic, erythorbic, itaconic, citric, aspartic, glutamic, histidine, and ascorbic.
• Example 4 The lower solubility of the sertraline chloride salt and of all sertraline lactate and sertraline acetate salts in the presence of high chloride concentrations suggest that core formulations are preferred for which sertraline stays in solution that is, it does not precipitate or form a gel-like material when chloride is present. Certain organic acids and salts were found to inhibit precipitation or gelation of sertaiine when chloride is present via the following screening test. Sertraline lactate was dissolved in water either alone (as a control) or with a candidate solubilizing agent. Sodium chloride was then added (as a concentrated solution) and the result observed. An excipient was considered beneficial if the solution remained clear and fluid.
• Organic compounds were screened for their ability to enhance the solubility of sertraline lactate in aqueous solutions with or without the presence of chloride. Excess sertraline lactate was added to an aqueous solution of the candidate solubiiizer and, in most cases an organic acid. The organic acids were saturated in these solutions and the additional solubilizing agents were at the concentration shown in Table 5-1. The equilibrium sertraline solubility was measured. Then, sodium chloride was added to the saturated solution and the final sertraline concentration was measured. The results of these screening tests are summarized in Table 5-1.
• solubilizers for sertraline also can increase the rate of dissolution of sertraline.
• the effect of a candidate excipient on sertraline dissolution rate was determined by adding solid drug, the candidate solubilizing excipient, and, in some cases, other excipients such as an organic acid and an osmagent (such as a sugar) to a 1.8 ml centrifuge tube.
• the sample tubes were spun at 14K G for 5 minutes in a microcentrifuge to pack the powder.
• 150 ⁇ l gastric buffer was added to the packed powder and the samples were gently agitated, then spun at 14K G in a microcentrifuge for 2 minutes.
• This examples illustrates a method for making osmotic tablets comprising a tablet core containing sertraline with and without solubilizing agents surrounded by a semipermeable asymmetric membrane coating.
• Sertraline-hydrochloride was triturated by hand for 10 minutes with citric acid and microcrystalline cellulose (Avicel PH 102, FMC) using a 6 1/2 inch diameter mortar and pestle. Magnesium stearate was then blended in as a lubricant by stirring with a spatula for 60 seconds.
• the weight ratio of sertraline-hydrochloride to citric acid to microcrystalline cellulose to magnesium stearate was 8.5:63.8:23.7:4; with a total weight of 10 grams.
• the blended mixture was pressed into 470 mg tablets in a modified hydraulic jack (manufactured by Dayton) fitted with a pressure gauge and 3/8 inch concave punch under 2500 PSI pressure for 2 seconds.
• the dimensions of the resulting tablets were 3/8 inch in diameter and 1/4 inch thick.
• a semipermeable membrane coating (as described in U.S. Patent 5,612,059 was applied to these tablets using a LDCS-20 pan coater (Vector Corp.) at a spray rate of 20 grams per minute, an inlet temperature of 40°C and air flow of 40 cfm.
• the coating solution contained by weight 10% Cellulose acetate, (Eastman Chemical, CA398-10), 2.5% polyethylene glycol (BASF, PEG 3350), 15% water and 72.5% acetone.
• the coated tablets were dried 1 hour at 50°C before testing. After drying, the weight of applied coating material was 15.4% of the total weight.
• Additional osmotic delivery tablets were prepared by using essentially the same procedure for making the tablet cores and applying the asymmetric membrane coating to the cores described above.
• the composition of the cores and coating solution varied as shown in Table 7-1. Significant core compositional changes shown include: the sertraline salt form, the type and amount of solubiiizer, and the type and amount of osmagent.
• binder (Avicel ® ) lubricant (magnesium stearate), and solubiiizer were varied as necessary to obtain good tableting and wetting properties. These tablets all contained a sertraline dose of 50 mgA/tablet. Table 7-1
• the rates of release of sertraline from these formulations were determined testing the tablets in a USP Apparatus #2 with paddle stirring speed set at 100 rpm.
• the receptor solution used in the dissolution apparatus was 0.13M acetate buffer at pH 4.0 with 0.075M sodium chloride kept at 37°C. Samples of the receptor solution were taken at the times shown in Table 7-2. Analysis of sertraline released was determined by reverse-phase high-performance liquid chromatography (RP HPLC).
• Table 7-2 The results of release-rate tests performed using these procedures are listed in Table 7-2.
• the first two formulations listed, 7a and 7b show low release rates and are included as comparison examples. Both these formulations contain a sertraline salt (hydrochloride or lactate) and only lactose as the osmagent and no solubilizing excipients.
• the remaining formulations (7c-7h) listed in Table 7-2 all contain one or more solubilizing excipients and all demonstrate significantly higher release rates of sertraline compared with the formulations that do not contain solubilizers.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Epidemiology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Neurosurgery (AREA)
• Organic Chemistry (AREA)
• Neurology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Biomedical Technology (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Biophysics (AREA)
• Molecular Biology (AREA)
• Inorganic Chemistry (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Medicinal Preparation (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Applications Claiming Priority (3)

Publications (1)

Family

ID=21971159

Family Applications (1)

Country Status (34)

Families Citing this family (8)

Family Cites Families (3)

• 1998
  • 1998-06-15 EA EA199900962A patent/EA002481B1/ru unknown
  • 1998-06-15 IL IL13307698A patent/IL133076A/xx not_active IP Right Cessation
  • 1998-06-15 AU AU75448/98A patent/AU742535B2/en not_active Ceased
  • 1998-06-15 UA UA99116391A patent/UA67741C2/uk unknown
  • 1998-06-15 ID IDW991701A patent/ID23429A/id unknown
  • 1998-06-15 YU YU68299A patent/YU68299A/sh unknown
  • 1998-06-15 CA CA002290974A patent/CA2290974C/en not_active Expired - Fee Related
  • 1998-06-15 JP JP11506774A patent/JP2000514100A/ja active Pending
  • 1998-06-15 BR BR9810739-9A patent/BR9810739A/pt not_active Application Discontinuation
  • 1998-06-15 TR TR1999/03297T patent/TR199903297T2/tr unknown
  • 1998-06-15 EP EP98923019A patent/EP0999829A1/en not_active Withdrawn
  • 1998-06-15 SK SK1810-99A patent/SK181099A3/sk unknown
  • 1998-06-15 HU HU0002236A patent/HUP0002236A3/hu unknown
  • 1998-06-15 CN CN98806763A patent/CN1261794A/zh active Pending
  • 1998-06-15 PL PL98337804A patent/PL337804A1/xx unknown
  • 1998-06-15 KR KR10-1999-7011361A patent/KR100366373B1/ko not_active IP Right Cessation
  • 1998-06-15 WO PCT/IB1998/000933 patent/WO1999001120A1/en not_active Application Discontinuation
  • 1998-06-25 TW TW087110267A patent/TW550087B/zh active
  • 1998-06-25 AP APAP/P/1998/001280A patent/AP1192A/en active
  • 1998-06-26 PE PE1998000573A patent/PE97199A1/es not_active Application Discontinuation
  • 1998-06-29 AR ARP980103146A patent/AR015917A1/es not_active Application Discontinuation
  • 1998-06-29 PA PA19988454301A patent/PA8454301A1/es unknown
  • 1998-06-29 UY UY25071A patent/UY25071A1/es not_active IP Right Cessation
  • 1998-06-30 DZ DZ980158A patent/DZ2548A1/xx active
  • 1998-06-30 MA MA25146A patent/MA24587A1/fr unknown
  • 1998-06-30 TN TNTNSN98124A patent/TNSN98124A1/fr unknown
  • 1998-06-30 ZA ZA9805708A patent/ZA985708B/xx unknown
  • 1998-07-01 HR HR60/051,413A patent/HRP980377A2/hr not_active Application Discontinuation
  • 1998-07-01 HN HN1998000102A patent/HN1998000102A/es unknown
  • 1998-07-01 CO CO98037137A patent/CO4940495A1/es unknown
• 1999
  • 1999-11-19 IS IS5260A patent/IS5260A/is unknown
  • 1999-11-23 BG BG103918A patent/BG103918A/xx unknown
  • 1999-12-21 OA OA9900301A patent/OA11243A/en unknown
  • 1999-12-28 NO NO996520A patent/NO996520L/no not_active Application Discontinuation
• 2003
  • 2003-06-19 AR ARP030102179A patent/AR040279A2/es unknown
  • 2003-06-19 AR ARP030102180A patent/AR040280A2/es unknown

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events